Is GlucoTrack Stock a Good Investment?
GlucoTrack Investment Advice | GCTK |
- Examine GlucoTrack's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research GlucoTrack's leadership team and their track record. Good management can help GlucoTrack navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact GlucoTrack's business and its evolving consumer preferences.
- Compare GlucoTrack's performance and market position to its competitors. Analyze how GlucoTrack is positioned in terms of product offerings, innovation, and market share.
- Check if GlucoTrack pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about GlucoTrack's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in GlucoTrack stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if GlucoTrack is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine GlucoTrack Stock
Researching GlucoTrack's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book (P/B) ratio of 0.46. Some equities with similar Price to Book (P/B) outperform the market in the long run. GlucoTrack recorded a loss per share of 3442.8. The entity had not issued any dividends in recent years. The firm had 1:60 split on the 16th of June 2025.
To determine if GlucoTrack is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding GlucoTrack's research are outlined below:
| GlucoTrack generated a negative expected return over the last 90 days | |
| GlucoTrack has high historical volatility and very poor performance | |
| GlucoTrack has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (22.6 M) with loss before overhead, payroll, taxes, and interest of (20 K). | |
| GlucoTrack currently holds about 3.85 M in cash with (12.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.25. | |
| GlucoTrack has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: GlucoTrack Inc. Stock Analysis and Forecast - Breakthrough capital growth - Jammu Links News |
GlucoTrack uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in GlucoTrack. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to GlucoTrack's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know GlucoTrack's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as GlucoTrack is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading GlucoTrack backward and forwards among themselves. GlucoTrack's institutional investor refers to the entity that pools money to purchase GlucoTrack's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Virtu Financial Llc | 2025-03-31 | 51.2 K | Hrt Financial Llc | 2025-03-31 | 35.2 K | Xtx Topco Ltd | 2025-03-31 | 13.8 K | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 25.0 | Sbi Securities Co Ltd | 2025-03-31 | 18.0 | Bank Of America Corp | 2025-03-31 | 4.0 | Cetera Investment Advisers | 2024-12-31 | 0.0 | Alerus Financial Na | 2024-12-31 | 0.0 | Ubs Group Ag | 2024-12-31 | 0.0 |
GlucoTrack's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.36 M.Market Cap |
|
GlucoTrack's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 3.81 | 4.00 | |
| Return On Capital Employed | (3.12) | (2.97) | |
| Return On Assets | 3.81 | 4.00 | |
| Return On Equity | (1.74) | (1.65) |
Determining GlucoTrack's profitability involves analyzing its financial statements and using various financial metrics to determine if GlucoTrack is a good buy. For example, gross profit margin measures GlucoTrack's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of GlucoTrack's profitability and make more informed investment decisions.
Evaluate GlucoTrack's management efficiency
GlucoTrack has return on total asset (ROA) of (1.6101) % which means that it has lost $1.6101 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.9434) %, meaning that it created substantial loss on money invested by shareholders. GlucoTrack's management efficiency ratios could be used to measure how well GlucoTrack manages its routine affairs as well as how well it operates its assets and liabilities. At this time, GlucoTrack's Return On Tangible Assets are quite stable compared to the past year. Return On Assets is expected to rise to 4.00 this year, although the value of Return On Capital Employed is projected to rise to (2.97). At this time, GlucoTrack's Total Current Liabilities is quite stable compared to the past year. Non Current Liabilities Total is expected to rise to about 18.5 M this year, although the value of Liabilities And Stockholders Equity will most likely fall to about 4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (34.95) | (36.70) | |
| Tangible Book Value Per Share | (34.95) | (36.70) | |
| Enterprise Value Over EBITDA | 0.12 | 0.12 | |
| Price Book Value Ratio | (0.21) | (0.20) | |
| Enterprise Value Multiple | 0.12 | 0.12 | |
| Price Fair Value | (0.21) | (0.20) | |
| Enterprise Value | -2.3 M | -2.4 M |
Understanding the operational decisions made by GlucoTrack management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta (0.19) |
Basic technical analysis of GlucoTrack Stock
As of the 19th of July, GlucoTrack retains the Market Risk Adjusted Performance of (0.22), standard deviation of 8.99, and Risk Adjusted Performance of (0.03). GlucoTrack technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.GlucoTrack's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific GlucoTrack insiders, such as employees or executives, is commonly permitted as long as it does not rely on GlucoTrack's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases GlucoTrack insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
GlucoTrack's Outstanding Corporate Bonds
GlucoTrack issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. GlucoTrack uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most GlucoTrack bonds can be classified according to their maturity, which is the date when GlucoTrack has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US45824TBC80 Corp BondUS45824TBC80 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| IFCCN 5459 22 SEP 32 Corp BondUS45823TAL08 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| INTELLIGENT PACKAGING LTD Corp BondUS45827MAA53 | View |
Understand GlucoTrack's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing GlucoTrack's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.22) | |||
| Mean Deviation | 5.45 | |||
| Coefficient Of Variation | (2,187) | |||
| Standard Deviation | 8.99 | |||
| Variance | 80.89 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.66) | |||
| Total Risk Alpha | (1.68) | |||
| Treynor Ratio | (0.23) | |||
| Maximum Drawdown | 59.67 | |||
| Value At Risk | (11.95) | |||
| Potential Upside | 10.7 | |||
| Skewness | (0.74) | |||
| Kurtosis | 6.0 |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.22) | |||
| Mean Deviation | 5.45 | |||
| Coefficient Of Variation | (2,187) | |||
| Standard Deviation | 8.99 | |||
| Variance | 80.89 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.66) | |||
| Total Risk Alpha | (1.68) | |||
| Treynor Ratio | (0.23) | |||
| Maximum Drawdown | 59.67 | |||
| Value At Risk | (11.95) | |||
| Potential Upside | 10.7 | |||
| Skewness | (0.74) | |||
| Kurtosis | 6.0 |
Consider GlucoTrack's intraday indicators
GlucoTrack intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of GlucoTrack stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
GlucoTrack Corporate Filings
8K | 8th of July 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 28th of April 2025 Other Reports | ViewVerify | |
| 18th of April 2025 Other Reports | ViewVerify | |
F4 | 31st of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
GlucoTrack Stock media impact
There is far too much social signal, news, headlines, and media speculation about GlucoTrack that are available to investors today. This information is accessible both publicly - through GlucoTrack's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of GlucoTrack-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of GlucoTrack news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of GlucoTrack relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to GlucoTrack's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive GlucoTrack alpha.
GlucoTrack Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards GlucoTrack can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
GlucoTrack Historical Investor Sentiment
Investor biases related to GlucoTrack's public news can be used to forecast risks associated with an investment in GlucoTrack. The trend in average sentiment can be used to explain how an investor holding GlucoTrack can time the market purely based on public headlines and social activities around GlucoTrack. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
GlucoTrack's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for GlucoTrack and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average GlucoTrack news discussions. The higher the estimate score, the more favorable the investor's outlook on GlucoTrack.
GlucoTrack Corporate Management
| Erez BenZvi | GM Product | Profile | |
| Drinda Benjamin | Vice Marketing | Profile | |
| Paul Goode | Chief Officer | Profile | |
| MScEE MBA | Chairman CoFounder | Profile | |
| Mark Tapsak | Vice Technology | Profile | |
| Esq CPA | Chief Officer | Profile | |
| David BA | CoFounder | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlucoTrack. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy GlucoTrack Stock please use our How to buy in GlucoTrack Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlucoTrack. If investors know GlucoTrack will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlucoTrack listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of GlucoTrack is measured differently than its book value, which is the value of GlucoTrack that is recorded on the company's balance sheet. Investors also form their own opinion of GlucoTrack's value that differs from its market value or its book value, called intrinsic value, which is GlucoTrack's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlucoTrack's market value can be influenced by many factors that don't directly affect GlucoTrack's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between GlucoTrack's value and its price, as these two are different measures arrived at by various means. Investors typically determine if GlucoTrack is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlucoTrack's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.